BDF Gestion Sells 580 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BDF Gestion reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,453 shares of the biopharmaceutical company's stock after selling 580 shares during the quarter. BDF Gestion's holdings in Regeneron Pharmaceuticals were worth $2,824,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Brighton Jones LLC lifted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after buying an additional 686 shares during the period. Savant Capital LLC raised its stake in Regeneron Pharmaceuticals by 21.2% during the fourth quarter. Savant Capital LLC now owns 985 shares of the biopharmaceutical company's stock valued at $701,000 after buying an additional 172 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Regeneron Pharmaceuticals by 56.1% during the fourth quarter. Vontobel Holding Ltd. now owns 6,458 shares of the biopharmaceutical company's stock valued at $4,600,000 after buying an additional 2,322 shares during the last quarter. Manchester Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 18 shares during the last quarter. Finally, Principal Securities Inc. raised its stake in Regeneron Pharmaceuticals by 43.9% during the fourth quarter. Principal Securities Inc. now owns 898 shares of the biopharmaceutical company's stock valued at $640,000 after buying an additional 274 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $529.24 on Monday. The stock has a 50 day moving average of $563.19 and a 200 day moving average of $648.52. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a market cap of $57.14 billion, a PE ratio of 13.83, a PEG ratio of 2.34 and a beta of 0.31. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Royal Bank of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price for the company. in a report on Friday, May 30th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Finally, UBS Group cut their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $836.48.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.